Enzon Pharmaceuticals Inc. (ENZN) 10.53 +0.20

Trade ENZN
NOW!
Last Trade:10.24Short Ratio:12.70
Last Trade Time:4:00pmDay Range:9.98 - 10.26
Ask:10.53Year Range:5.40 - 11.50
Bid:10.04One Year Target:12.67
Open:9.98Exchange:NGM
Volume:981691EBITDA:21.9M
Prev. Close:10.04Market Cap:463.7M
50 Day Moving:9.583Div Yield:
200 day moving:9.471PE:436.52

SmarTrend's Candlestick Scanner Detects Bearish Harami Pattern for Enzon Pharmaceuticals (ENZN)

Posted on 03/12/10 at 8:54am
SmarTrend's candlestick pattern scanner has detected a bearish harami candle pattern for shares of Enzon Pharmaceuticals (NASDAQ: ENZN). Yesterday's real body is within the previous day's body and may imply that traders and investors believe that the recent uptrend may be nearing an end.
Click here to read the rest of the article

Enzon’s Debt is Reduced by $116 Million

Posted on 03/08/10 at 11:12am
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced the results from the recent tender and increased conversion periods of the 4 percent convertible notes due in 2013.
Click here to read the rest of the article

Enzon Pharmaceuticals: The Trend Continues Down (ENZN)

Posted on 02/25/10 at 4:50pm
SmarTrend identified a Downtrend for Enzon Pharmaceuticals (NASDAQ: ENZN) on January 27, 2010 at $9.87. In approximately 4 weeks, Enzon Pharmaceuticals has returned 6.8% as of today's recent price of $9.20.
Click here to read the rest of the article

Enzon Opens Pediatric Study of PEG-SN38

Posted on 02/24/10 at 4:11pm
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that the first patient has been treated in the Phase 1 study of PEG-SN38 for pediatric cancer patients.
Click here to read the rest of the article

Enzon Board of Directors Appoints Executive Committee

Posted on 02/23/10 at 2:55pm
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that Jeffrey Buchalter has resigned as Chief Executive Officer and Director of Enzon, effective immediately, and has been replaced by a newly formed executive committee of the Board.
Click here to read the rest of the article

Enzon Pharmaceuticals: Making a Move, Down 0.7% (ENZN)

Posted on 02/23/10 at 2:52pm
Enzon Pharmaceuticals (NASDAQ: ENZN) is one of today's worst performing stocks, down 0.7% to $9.35. The S&P is currently trading 0% lower to 1,109 and the Dow Jones Industrial Average is trading 0% lower to 10,397.
Click here to read the rest of the article

Enzon Pharmaceuticals Downward Momentum Looks to Continue (ENZN)

Posted on 02/18/10 at 3:03pm
SmarTrend identified a Downtrend for Enzon Pharmaceuticals (NASDAQ: ENZN) on January 27, 2010 at $9.87. In approximately 3 weeks, Enzon Pharmaceuticals has returned 6.8% as of today's recent price of $9.19.
Click here to read the rest of the article

Enzon Reports 2009 Results

Posted on 02/17/10 at 9:39am
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced its financial results for 2009.
Click here to read the rest of the article

The CEO Roundtable on Cancer Salutes Duke Men’s Basketball Head Coach Mike Krzyzewski On His 1000th Game

Posted on 02/12/10 at 6:31pm
CARY, N.C.--(BUSINESS WIRE)-- The CEO Roundtable on Cancer salutes Mike Krzyzewski, who on Saturday, February 13th will celebrate his 1000th game leading the Duke Blue Devils men’s basketball team.
Click here to read the rest of the article

Immunomedics Appoints Kenneth J. Zuerblis to Board of Directors

Posted on 02/10/10 at 9:33am
MORRIS PLAINS, N.J., Feb. 10, 2010 (GLOBE NEWSWIRE) -- Immunomedics, Inc.
Click here to read the rest of the article